Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Novo Nordisk's CagriSema Leads to Superior Weight Loss in REDEFINE 1 Trial Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit VisualAbstract: Combined cagrilintide and semaglutide for weight management well tolerated in early clinical trials 2 Minute Medicine Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine